Topic: Breaking Research News from Breastcancer.org

Forum: Clinical Trials, Research News, Podcasts, and Study Results — Share your research articles, interpretations and experiences here. Let us know how these studies affect you and your decisions.

Posted on: Apr 16, 2012 05:33PM - edited Jan 16, 2016 07:28PM by moderators

Posted on: Apr 16, 2012 05:33PM - edited Jan 16, 2016 07:28PM by moderators

moderators wrote:

Breastcancer.org strives to bring you updates on the latest breast cancer research through its Research News program. Medical experts at Breastcancer.org provide easy-to-understand summaries of what the research means for YOU.

Check out this thread on a regular basis to see all the breaking news about current breast cancer research from our experts.

Get Personalized Research News Stories JUST for You!
Don't forget to fill out your profile: In the top right hand corner of the screen, under My Profile, you'll find My Diagnoses and My Treatments. Once you've provided enough information, we'll send recommended articles. Members can save these articles for later, or archive them when they're finished with them.

If you would like to receive Personalized Research News articles, based on diagnosis and treatment information, you'll need to go into "My Profile" and under the "Recommended Articles", click "turn on".

To send a PM to the Mods: community.breastcancer.org/my/...
Log in to post a reply

Page 1 of 123 (1,228 results)

Log in to post a reply

Apr 16, 2012 05:34PM moderators wrote:

Adding Ultrasound and MRI to Annual Mammograms Helps Find More Cancers in Women with Dense Breasts
April 3, 2012
Screening plans that add ultrasound and MRI to annual mammograms improves breast cancer detection in women with dense breasts. Read more...
To send a PM to the Mods: community.breastcancer.org/my/...
Log in to post a reply

Apr 16, 2012 05:34PM - edited Apr 14, 2020 12:41PM by moderators

This Post was deleted by moderators.
To send a PM to the Mods: community.breastcancer.org/my/...
Log in to post a reply

Apr 16, 2012 05:35PM - edited Apr 14, 2020 12:42PM by moderators

This Post was deleted by moderators.
To send a PM to the Mods: community.breastcancer.org/my/...
Log in to post a reply

Apr 16, 2012 08:39PM - edited Apr 14, 2020 12:43PM by moderators

This Post was deleted by moderators.
To send a PM to the Mods: community.breastcancer.org/my/...
Log in to post a reply

Apr 19, 2012 05:21PM dunesleeper wrote:

Rulebook on breast cancer rewritten
ANI | Apr 19, 2012, 12.05PM IST

Rulebook on breast cancer rewritten (Thinkstock photos/Getty Images)
Scientists have identified new breast cancer genes that could revolutionise treatment for thousands of women.

Researchers at the BC Cancer Agency and University of British Columbia have reclassified the disease into 10 completely new categories based on the genetic fingerprint of a tumour.

Many of these genes could offer much-needed insight into breast cancer biology, allowing doctors to predict whether a tumour will respond to a particular treatment.

Whether the tumour is likely to spread to other parts of the body or if it is likely to return following treatment.

The study is the largest global study of breast cancer tissue ever performed and the culmination of decades of research into the disease.

In the future, this information could be used by doctors to better tailor treatment to the individual patient.

The team at the BC Cancer Agency, in collaboration with Cancer Research UK's Cambridge Research Institute and Manitoba Institute of Cell Biology at University of Manitoba, analyzed the DNA and RNA of 2,000 tumour samples taken from women diagnosed with breast cancer between five and 10 years ago.

The sheer number of tumours mapped allowed researchers to spot new patterns in the data.

The new discovery identified genes that were previously unknown to be linked to breast cancer and made it clear that breast cancer is an umbrella term for what really is a number of unique diseases.

Till now, breast cancer had been classified into four subgroups.

"This won't affect women diagnosed today. But in the future, patients will receive treatment targeted to the genetic fingerprint of their tumour," the Daily Express quoted Professor Carlos Caldas, senior group leader at the charity's Cambridge Research Institute, as saying.

"We've moved from knowing what a breast tumour looks like to pinpointing its molecular anatomy. Eventually we'll know which drugs it will respond to.

"The next stage is to discover how tumours in each subgroup behave - for example, do they grow or spread quickly?" Prof Caldas added.

The study has been recently published in the international journal Nature.

timesofindia.indiatimes.com/li... 

Dx 2/7/2012, IDC, 4cm, Stage IIB, Grade 3, 1/31 nodes, ER+/PR+, HER2- Surgery 3/7/2012 Mastectomy: Right; Reconstruction (right): Tissue expander placement Surgery 9/4/2012 Reconstruction (right) Dx 8/20/2014, IDC, Stage IV, Grade 3, mets, ER+/PR+, HER2- Hormonal Therapy 8/20/2014 Arimidex (anastrozole) Dx 4/17/2015, IDC, Stage IV, Grade 3, ER+/PR+, HER2- Chemotherapy 5/4/2015 Taxol (paclitaxel) Chemotherapy 7/10/2015 Carboplatin (Paraplatin), Gemzar (gemcitabine) Radiation Therapy 9/1/2015 External: Bone Targeted Therapy 10/24/2015 Ibrance (palbociclib)
Log in to post a reply

Apr 20, 2012 01:08AM dunesleeper wrote:

http://www.latimes.com/health/la-he-breast-cancer-genetics-20120419,0,7505697.story

 Breast cancer classification promises better therapies
Researchers have devised 10 categories for breast cancer tumors, an important stride toward targeting treatments more precisely. The hope is to spare patients unnecessarily toxic therapies.

By Eryn Brown, Los Angeles Times

April 19, 2012

Researchers have found a way to classify breast cancer tumors into 10 distinct categories ranging from very treatable to extremely aggressive, a major step on the way to the long-sought goal of precisely targeting therapies for patients.

The new categories, described in a study released Wednesday, should help scientists devise fresh approaches to treat some of the cancers and could spare many women the risks and pain of unnecessarily toxic treatments, oncologists said.

"If you belong to one group you'll need one therapy, and if you're in another you'll need another," said Dr. Carlos Caldas, a breast cancer geneticist at the University of Cambridge in England who helped oversee the research. For some women, he added, tumor typing might indicate that traditional chemotherapy isn't warranted at all.

"A lot of women are being overtreated," he said. "Can we spare them that?"

The study, published by the journal Nature, is the first of many expected in the coming months that will use genetic clues in breast cancer tumors to help refine categories of the disease, which strikes 1 in 8 women in the U.S.

Doctors like to say that breast cancer is not a single disease, but a range of them. But because they don't completely understand which therapies will work for a given tumor and why, they tend to err on the side of caution - administering treatments in cases in which they may provide little benefit.

This type of research could begin to change that, experts said.

"This is going to have a huge impact on the way we think about breast cancer," said Raju Kucherlapati, a genetics professor at Harvard Medical School who was not involved in the study. "Together with other data coming out in the next few months, I think the whole landscape of research, discovery and treatment is going to change."

Clinicians already divide tumors into a few different types, and targeted treatments are available for some flavors of the disease. For instance, women with tumors that test positive for a cancer-promoting protein called HER2 often respond well to the drug Herceptin, which isn't effective against other types of tumors.

But in a frustratingly high number of cases, scientists can't explain why one woman will respond to a given treatment and another woman won't - even though they both might have tumors that are estrogen-receptor-positive, for example.

"It's not a very precise art," Caldas said.

Hoping to hone the process, Caldas and colleagues from Britain and Canada analyzed the genetic signatures of samples from 997 tumors, examining how aberrations in DNA turned various genes on and off. They analyzed 2 million spots on the genome, focusing on differences in the number of times a string of DNA is repeated and on small gene variations known as single nucleotide polymorphisms, or SNPs. They also looked at RNA, which helps translate DNA instructions into proteins, to gauge gene activity.

Then they correlated that data with long-term health outcomes of the women from whom the tumors were removed, establishing a link between the genetic patterns and how tumors progressed. The analysis involved complicated number-crunching and took more than five years to complete.

In the end, the research team identified 10 distinct subtypes of breast cancer. They reinforced previously known groups and were able to make further distinctions within them.

For example, they found that tumors in two of the categories had very few DNA aberrations compared with those in other groups. Tumors in one of these categories appeared to be more susceptible to an immune system attack, and they had one of the best profiles for prognosis.

"These tumors do have something different about them," Caldas said. And by studying them further, he suggested, researchers may discover that they respond well to novel treatments.

The team confirmed the validity of their categories by testing them in a separate group of 995 tumors.

Experts said the scale of the work was "remarkable," as Kucherlapati put it.

"The fact that they have 997 samples for discovery and 995 for validation makes it very special," he said.

Dr. John Glaspy, an oncologist at UCLA's Jonsson Comprehensive Cancer Center, added that the genetic analysis also sheds light on a fundamental question: How do cancers emerge?

"It's an insight into how this whole thing works," he said. "Insight is the beginning of new treatment."

But Glaspy and others also cautioned that the discovery would not revolutionize the practice of medicine right away.

"I want to make sure people won't see this and say, 'Game over!' " said Stephen Friend, cofounder of Sage Bionetworks in Seattle, a nonprofit organization that promotes collaborative medical research. In truth, he said, the ability to match genetic signatures to long-term cancer outcomes is a sign that "the game starts."

University of British Columbia breast cancer researcher Samuel Aparicio, another leader of the study, said scientists would need to conduct clinical trials to determine whether the gene aberrations the team identified could be effectively targeted with existing drugs. The findings should also help pharmaceutical companies create new drugs to fight breast cancer, he added.

"This should be a good stimulus" for industry, he said.

Complementary research is expected shortly from the National Cancer Institute's Cancer Genome Atlas and the Wellcome Trust Sanger Institute in Hinxton, England.

eryn.brown@latimes.com

Copyright © 2012, Los Angeles Times

Dx 2/7/2012, IDC, 4cm, Stage IIB, Grade 3, 1/31 nodes, ER+/PR+, HER2- Surgery 3/7/2012 Mastectomy: Right; Reconstruction (right): Tissue expander placement Surgery 9/4/2012 Reconstruction (right) Dx 8/20/2014, IDC, Stage IV, Grade 3, mets, ER+/PR+, HER2- Hormonal Therapy 8/20/2014 Arimidex (anastrozole) Dx 4/17/2015, IDC, Stage IV, Grade 3, ER+/PR+, HER2- Chemotherapy 5/4/2015 Taxol (paclitaxel) Chemotherapy 7/10/2015 Carboplatin (Paraplatin), Gemzar (gemcitabine) Radiation Therapy 9/1/2015 External: Bone Targeted Therapy 10/24/2015 Ibrance (palbociclib)
Log in to post a reply

Apr 21, 2012 02:00PM moderators wrote:

Adolescent Drinking Boosts Benign Breast Disease Risk
April 18, 2012
New results from the Nurses' Health Study II show a strong link between drinking alcohol during adolescence and the risk of being diagnosed with benign breast disease. Read more...
To send a PM to the Mods: community.breastcancer.org/my/...
Log in to post a reply

Apr 21, 2012 07:00PM moderators wrote:

Large Review Study Confirms Herceptin's Benefits
April 20, 2012
A large review study has found that women diagnosed with HER2-positive breast cancer and treated with Herceptin were less likely to have the cancer come back and more likely to survive compared to women who didn't get Herceptin. Read more...
To send a PM to the Mods: community.breastcancer.org/my/...
Log in to post a reply

Apr 23, 2012 08:59PM - edited Apr 14, 2020 12:44PM by moderators

This Post was deleted by moderators.
To send a PM to the Mods: community.breastcancer.org/my/...
Log in to post a reply

Apr 25, 2012 11:37PM - edited Apr 14, 2020 12:46PM by moderators

This Post was deleted by moderators.
To send a PM to the Mods: community.breastcancer.org/my/...

Page 1 of 123 (1,228 results)

Scroll to top button